Press
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the successful renewal of their SOC 2 Type II compliance certification with an unqualified opinion, also known as a clean report, following a rigorous independent audit. The SOC 2 Type II audit is conducted by independent, third-party auditors to determine whether a company is maintaining enterprise-level data security through its operations, controls, and processes. This renewal highlights Tasso’s continuing commitment to meeting the highest industry standards and demonstrates the company’s ability to securely manage client data.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, surveyed more than 600 adults (age 18-65+) within the United States to assess their experiences and preferences regarding blood testing, as well as their perspectives about the future of patient care. The survey, titled Patient Preferences, Perceptions, and the Evolving Challenges of Ensuring Patient Compliance With Diagnostic Healthcare Testing, validated prevailing industry perspectives that the current status quo for blood collection underserves patients seeking more convenient and less painful options for blood collection.
InnoVero, a global leader in providing innovative, athlete-centric collection technologies to anti-doping organizations worldwide and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the extension of their partnership that was first initiated in 2021. In addition to collaboratively developing new athlete-centric solutions, InnoVero will continue to serve as the exclusive worldwide distributor of Tasso blood collection solutions for the anti-doping marketplace.
Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a new collaboration that will reduce patient burden in clinical trials requiring blood collection. Lindus Health will adopt Tasso’s virtually painless remote blood collection technology as an option for sponsors looking to enable simple, more cost-effective remote blood collection while conducting their clinical trials. This innovative method will allow participants to collect simple blood samples themselves at home without the need for a mobile phlebotomist or nurse.
The Leukemia & Lymphoma Society® (LLS), a global leader in the fight against blood cancer, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a collaboration to accelerate blood cancer research. The relationship will combine Tasso’s signature capillary blood collection technology with LLS’ research and focus on patient advocacy, with the goal of improving the oncology patient experience.
The Parkinson’s Foundation and Tasso, Inc. today announced a partnership to expand and accelerate genetic research into Parkinson’s disease (PD). The partnership leverages Tasso’s patient-centric, end-to-end sample collection and logistics platform to enable data collection for a landmark international genetics study by the Parkinson’s Foundation: PD GENEration: Mapping the Future of Parkinson’s.
Last week we accomplished a huge milestone and shipped our one millionth device. This was an incredible moment for our company as a whole and something that was hard to imagine when we first started out nearly 12 years ago.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program. The new offering expands the foundation and expertise of the Tasso Care services platform in remote blood collection and analysis to support clinical trial recruitment.
In 2023, Tasso achieved remarkable growth driven by our unwavering focus on expanding access to care for more patients by offering convenient diagnostic healthcare options. Our patient-centric blood collection solutions have proven to be a valuable addition to the pharmaceutical and healthcare industry. Several new engagements forged in the second half of 2023 support our continued growth and ability to offer more complete solutions to the industry.
Randox Health, which provides at-home and in-clinic health tests as part of Randox – the largest healthcare diagnostics company in the UK and Ireland – and Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced a partnership to offer at-home healthcare diagnostic testing powered by Tasso’s innovative blood collection technology.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the successful completion of the System and Organization Controls (SOC) 2 Type 2 audit. The SOC 2 Type 2 audit is conducted by independent auditors to determine whether a company is maintaining a high standard for handling sensitive client data through its operations, controls, and processes. The auditors observed Tasso’s operations against all five SOC 2 Trust Services Criteria (Security, Availability, Processing Integrity, Confidentiality, and Privacy) and found no exceptions. This achievement demonstrates Tasso’s ability to securely manage client data and highlights the company’s commitment to meeting the highest industry standards.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the appointment of Monica Williams as Chief Financial Officer, reporting to Tasso’s CEO Ben Casavant.
Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced it received CE Mark certification for its Tasso+™ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples. The CE Mark designation allows Tasso to offer its patient-centric, high-volume blood collection solution in the European Union (EU) market, which includes 28 member states, plus Iceland, Norway and Lichtenstein. The CE Mark designation ensures a product has met all European Commission safety, health and environmental protection requirements.
Artyc PBC, a California-based cold chain startup, announced today the launch of Artyc’s Medstow Mini, a small battery-powered cooling container designed to transport medical goods through the supply chain.
Tasso has continued to experience tremendous growth in 2023, fueled by new and expanded partnerships and increased demand for our patient-centric blood collection solutions. With our focus on expanding access to care for more patient populations, accelerating convenient at-home healthcare options and paving the way for a pivotal shift toward decentralized clinical trials, we continued to expand our capabilities and footprint, solidify partnerships and gain market traction.
Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC), a leading provider of evidence development solutions for the biopharmaceutical industry, today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.
Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, and Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today entered into a collaboration to offer Aptar Digital Health end-users access to Tasso’s devices for blood collection. The collaboration will focus on improving patient care through a simplified and integrated experience, delivering clinical value to patients through a real-world deployment and increasing adoption of new technologies by patients, providers and pharmaceutical companies.
CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), today announces that its TENOR device has obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that it has been recommended for certification from the Medical Device Single Audit Program (MDSAP), under which a single regulatory audit of a medical device manufacturer may satisfy the requirements of multiple regulatory jurisdictions participating in the program. The certification confirms Tasso’s compliance with the standards and regulatory requirements of Australia, Canada and the United States, opening potential new global markets for Tasso.
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection technology, today announced the appointment of Duncan Porter as Senior Vice President of Growth, reporting to Tasso’s CEO Ben Casavant. Porter will lead Tasso's international expansion, building upon the recent CE regulatory approval of their TassoOneTM Plus and Tasso-M20 devices.
Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that the TassoOne Plus, a new high-volume liquid blood collection device, has received CE Mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation.
Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.
Catapult Health, a virtual preventive care provider serving 3,500 employers with over 2 million covered lives, and Tasso Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced a collaboration that will simplify home-based preventive care for employees and their families. Effective October 5th, Catapult will start offering the Tasso+™ device as part of its VirtualCheckup, an innovative at-home annual wellness checkup that combines simple and virtually painless testing with face-to-face clinical video consultations.
Tasso, Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+™ lancet as a Class II medical device. The clearance allows the company to market and sell the device to more pharmaceutical companies, healthcare organizations, and academic institutions across the country, expanding access to a simple and virtually painless blood collection experience.
Tasso, Inc., a leader in clinical-grade blood collection solutions, today announced the launch of Tasso PopPK Solutions, an integrated patient-centric offering for Population Pharmacokinetics (“PopPK”). With the launch of Tasso PopPK Solutions, Tasso now enables pharmaceutical companies to operationalize pharmacokinetic studies as part of their decentralized clinical trial efforts. Tasso's remote, patient-centric solution supports the acquisition of scalable and convenient pharmacokinetic data, improving modeling accuracy and accelerating clinical trials.
Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
Vault Health, an innovative healthcare company bringing virtual care to millions, today announced a partnership with Tasso, Inc., a leader in simple clinical grade blood collection technology, to integrate Tasso products and logistics into Vault’s turnkey service offering. The new partnership will enable an improved, virtually painless sample collection experience for Vault customers.
Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million. The financing round was led by RA Capital Management and included participation from new investors the D.E. Shaw group, Senvest, InCube, and SVB Innovation Fund, as well as existing investors Foresite Capital, Hambrecht Ducera Growth Ventures, J2V, Cedars-Sinai, and Merck GHIF.
InnoVero LLC, maker of the innovative SAFESystem™ sample collection kit currently revolutionizing global anti-doping practices, today announced a partnership with Tasso, Inc. to become the exclusive worldwide distributor for Tasso blood collection devices for the anti-doping marketplace. The partnership will accelerate global efforts to expand consistent non-invasive anti-doping testing.
Tasso Inc., a pioneer in clinical-grade, at-home, self-sampling blood collection, today announced that its Tasso-M20 device has received a CE (Conformité Européene) Mark certification and has successfully fulfilled all of the European Union’s performance, safety, and relevant product requirements. With this marking, Tasso is now able to provide pharmaceutical companies, leading medical institutions, and government health centers across the European Union and other CE Mark geographies with a best-in-class diagnostic experience for their patients.